Zusammenfassung
Die erstmals 1951 synoptisch dargestellten chronischen myeloproliferativen Erkrankungen werden heute als Folge einer klonalen Transformation der hämatopoietischen Stammzellen verstanden [2, 15, 21]. Als charakteristisch gilt eine vermehrte Bildung und Akkumulation hämatopoietischer Zellen besonders in Knochenmark und Blut, aber auch in Leber und Milz (Tabelle 1). Vier Krankheitsentitäten mit unterschiedlicher Prognose können anhand klinischer, hämatologischer, histologischer und zytogenetischer Kriterien relativ sicher differenziert werden: die chronische myeloische Leukämie (CML), die essentielle Thrombozythämie (ET), die Polycythaemia vera (PCV) und die idiopathische Myelofibrose (IM) [29, 49]. Trotz der jeweils prädominanten Proliferation eines Zelltyps bestehen allerdings, zumindest in der Krankheitsfrühphase, fließende Übergänge zwischen den einzelnen Entitäten.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ahegg-Werter MJBP, Raemaekers JMM, de Pauw BE, Haanen C (1990) Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia. Blut 60: 37–40
Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L (1976) Polycythemia vera: Stem-cell and probable clonal origin of the disease. N Engl J Med 295: 913–916
Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alpha-2b as therapy for Ph′- positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 72: 642–647
Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H (1989) A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 58: 275–278
Anger B, Haug U, Seidler R, Heimpel H (1989) Polycythemia vera. A clinical study of 141 patients. Blut 59: 493–500
Barosi G, Liberato LN, Costa A, Ascari E (1989) Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 58: 271–274
Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, van Kessel AG, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306: 277–280
Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, Boiron M (1986) Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 58: 2440–2447
Bergsagel DE, Haas RH, Messner HA (1986) Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 13 (Suppl 2): 29–34
Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group Protocols. Semin Hematol 23: 132–143
Broxmeyer HE, Lu L,Platzer E, Feit C, Juliano L, Rubin BY (1983) Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage ( CFU-GM) progenitor cells. J Immunol 131: 1300–1305
Broxmeyer HE, Cooper S, Rubin BY, Taylor MW (1985) The synergistic influence of human interferon gamma and interferon alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these to inhibition by interferons at low oxygen tension in vitro. J Immunol 135: 2502–2506
Carlo-Stella C, Cazzola M, Ganser A, Bergamaschi G, Padrazzoli P, Hoelzer D, Ascari E (1988) Synergistic anti-proliferative effect of recombinant interferon-y with recombinant interferon-a on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). Blood 72: 1293–1299
Champlin RE, Golde DW (1985) Chronic myelogenous leukemia - recent advances. Blood 65: 1039–1047
Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6: 372–375
De Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp B, Groffen J, Stephenson JR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelogenous leukemia. Nature 300: 765–767
Denz H, Lechleitner M, Marth C, Daxenbichler G, Gastl G, Braunsteiner H (1985) Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematological malignancies. J Interferon Res 5: 147–157
Dölken G, Lange W, Siegert W, Finke J, Lohr GW (1989) Polymerase chain reaction for the detection of chimeric BCR-ABL mRNAs in patients with chronic myelogenous leukemia - detection of minimal residual disease after bone marrow transplantation. Mol Biother 1 ( Suppl ): Abstr. 79
Ellis JT, Peterson P, Geller SA, Rappaport H (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 23: 144–155
Espinosa E, De Castro R, Carnot J, Dorticos E, Estrada M, Gonzalez X, Hernandez P, Travieso J, Vega G, Vidal H, Ramirez V, Limonta M (1986) Treatment of chronic myelocytic leukemia with human leukocyte alpha interferon. Abstr. 2nd Cuban Sem Interferon Biotechnol, Havana
Fialkow PJ, Jacobson RJ, Papayannopoulou T (1977) Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Amer J Med 63: 125–130
Fleischmann WR, Fleischmann CM, Fiers W (1984) Potentiation of interferon action by mixtures of recombinant DNA-derived human interferons. Antiviral Res 4: 357–360
Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoda H (1989) Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Brit J Haematol 73: 350–356
Freund M, Fonatsch C, Blessmann B, Tischler J, Eisert R, von Wussow P, Exeriede G, Hiddemann W, Link H, Wilke H, Buhr Th, Poliwoda H (1989) Interferon alpha-2b (IFN alpha-2b) in CML. Experiences with two treatment regimens. Mol Biother 1 ( Suppl ): Abstr 78
Friche E, Hansen MM, Wieslander S (1988) Refractoriness to -interferon ( Intron A) in previously chemotherapy-treated patients with chronic myelocytic leukaemia. Eur J Haematol 40: 305–308
Gastaut JA (1988) Le chromosome Philadelphie disparaît-il après traitement par l’interferon? Presse Méd 17: 639–644
Gastl G, Aulitzky Q, Tilg H, Huber H, Hausmaninger H, Seewann HL, Coser C, Prinoth P, Huber C (1987) Dose related effectiveness of alpha interferon in chronic myelogenous leukemia. Blut 54: 251–252
Gastl (persönliche Mitteilung), 1989
Georgii A (1982) Klassifikation der chronischen myeloproliferativen Erkrankungen durch Histopathologic und Zytogenetik des Knochenmarkes. (Karger, Basel) Beitr Onkol 13: 166–188
Giles FJ, Singer CRJ, Gray AG, Yong KL, Brozovic M, Davies SC, Grant IR, Hoffbrand AV, Machin SJ, Mehta AB, Richards JDM, Thomas MJG, Venutas S, Goldstone AH (1988) Alpha-interferon therapy for essential thrombocythaemia. Lancet 2: 70–72
Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz TH (1989) Long- term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1: 634–637
Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldman H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202–207
Gonzales R, Robinson W, Adlakha A, Lamb R, Rovira D, Ferguson J, Saks S, Bunn P (1989) Efficacy and toxicity of gamma interferon in chronic myelogenous leukemia. Proc Am Soc clin Oncol 8: 209
Greenberg PL, Mosny SA (1977) Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Res 37: 1794–1799
Guilhot F, Tanzer J, Brizard A, Dreyfus B, Huret JL, Desmarest MC, Briaut S (1988) Traitement de la leucémie myeloide chronique par interferon alpha recombinant et hydroxyuree. La Presse Médicale 17: 1491
Hasselbalch H (1988) Interferon in myelofibrosis. Lancet 1: 355
Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L, Kolb HJ, Meyer P, Essers U, Queißer U, Vaupel H, Walther F, Hossfeld DK, Zimmermann R, Heiss F, Mende S, Tigges FJ, Kleeberg UR, Pralle H, Kayser W, Zimmermann R, Tichelli A, Faulhaber JD, Räth U, Schubert H, Bross K, Schlag R, Schmid L, Weißenfels I, Heinze B, Georgii A, Queißer W, Heimpel H (1988) Randomized study on the treatment of chronic myeloid leukemia ( CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 56: 87–91
Hehlmann R, Jahn M, Baumann B, Kopeke W (1988) Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 61: 2487–2496
Herrmann F, Lindemann A, Otto J, Mertelsmann R (1988) In vivo effects of interferon- gamma in chronic myelogenous leukemia. In: Huhn D, Hellriegel KP, Niederle N (Eds.): Chronic Myelocytic Leukemia and Interferon. Pathophysiological, Clinical and Therapeutical Aspects. Springer-Verlag Berlin Heidelberg New York London Paris Tokyo: 113–118
Howard OMZ, Talpaz M, Kartarjian HM, Wedrychowski A, Seong D, Turpin J, Gutterman J, Freireich E, Deisseroth A (1989) Clinical responsiveness to alpha-interferon correlates with interferon-induced changes in binding of nuclear proteins to regulatory regions of interferon-inducible genes in CML. Proc Am Soc Clin Oncol 8: 7
Kantarjian HM,Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B. Trujillo J, Freireich EJ (1985) Intensive combination polychemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3: 192–200
Kantarjian H, Talpaz M, Keating M, Walters R, Estey E, Andersson B, Beran M, Trujillo J, McCredie K, Freireich E (1986) Therapy of Philadelphia chromosome positive chronic myelogenous leukemia with initial intensive chemotherapy (DOAP) followed by maintenance with human leukocyte alpha interferon (IFN-A). Blood 68 (Suppl 1), 224a
Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R (1985) The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 140: 230–238
Kloke O, Becher R, Niederle N (1987) Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia. Blut 55: 453–458
Kloke O, Moritz T, Piadeck E, Nagel-Hiemke M, Niederle N (1989) Combined administration of IFN alfa and TNF alfa in patients with chronic myelogenous leukemia and secondary resistence to IFN. Mol Biother 1 ( Suppl ): Abstr. 104
Koeffler HP, Golde DW (1981) Chronic myelogenous leukemia - new concepts. N Engl J Med 304: 1201–1209
Kurzrock R, Talpaz M, Kantarijian H, Walters R, Saks S, Trujillo JM, Gutterman JU Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70: 943–947
Landaw SA (1986) Acute leukemia in polycythemia vera. Semin Hematol 23: 156–165
Laszlo J (1975) Myeloproliferative disorders (MPD): Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 12: 409–432
Lee M-S, Chang K-S, Freireich EJ, Kantarjian HM, Talpaz M, Trujillo JM, Stass SA (1988) Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood 72: 893–897
Lee M-S, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA (1989) Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood 73: 2165–2170
Loeffler H, Schmitz N (1988) Allogeneic bone marrow transplantation for CML in Austria and West Germany. Blut 57: 221
Mahmoud HK, Schaefer UW, Schüning F, Beelen D, Becher R, Schmidt CG, Alberts W, Haralambie E, Linzenmeier G, Stollmann B, Grosse-Wilde H, Richter HJ, Hantschke D, Luboldt W (1985) Bone marrow transplantation for chronic granulocytic leukemia. Klin Wschr 63: 560–564
Manoharan A(1988) Annotation. Myelofibrosis: Prognostic factors and treatment. Brit. J. Haematol 69: 295–298
May D, Wandl UB, Niederle N (1989) Treatment of essential thrombocythaemia with interferon alpha-2b. Lancet 1: 96
McGlave P, Mamus S, Vilen B, Dewald G (1987) Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp Hematol 15: 331–335
Mills KI, MacKenzie ED, Birnie GD (1988) The site of the breakpoint within bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 72: 1237–1241
Murphy S, Iland H, Rosenthal D, Laszlo J (1986) Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 23: 177–182
Neumann HA, Fauser AA (1982) Effect of interferon on pluripotent hemopoietic progenitors ( CFU-GEMM) derived from human bone marrow. Exp Hematol 10: 587–590
Niederle N, Kurschel E, Schmidt CG (1984) Biologischer Effekt von rekombinantem Leukozyten-alpha2-Interferon bei metastasierten kolorektalen Karzinomen. Dtsch med Wschr 109, 779–782
Niederle N, Kurschel E, Schütte J, Krischke W, Schmidt CG, Gerlis L, Gutzwiller E (1985) Phase I study of recombinant human interferon gamma (rlFN-y) in patients with advanced cancer. In: Kirchner H, Schellekens H (Eds.): The Biology of the Interferon System 1984. Amsterdam Elsevier, 509–515
Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG (1987) Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 14 (Suppl 2): 29–35
Niederle N, Kloke O, Osieka R, May D, Wandl UB, Becher R, Opalka B, Schmidt CG (1988) Treatment of chronic and acute phase chronic myelogenous leukemia with interferon alpha-2b and interferon gamma. In: Huhn D, Hellriegel KP, Niederle N (Eds.): Chronic Myelocytic Leukemia and Interferon. Pathophysiological, Clinical and Therapeutical Aspects. Springer-Verlag, Berlin - Heidelberg - New York - London - Paris - Tokyo: 119–128
Niederle N, Wandl U, Kloke O, Nagel-Hiemke M, May D, Becher R, Overkamp F, Opalka B, Schmidt CG (1989) Efficacy of interferon alfa (IFN alfa-2b) and I FN gamma in chronic myelogenous leukemia ( CML ). Proc Am Soc Clin Oncol 8: 185
Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497
Opalka B, Kloke O, Bartram CR, Beer U, Janssen JWG, Wandl UB, Niederle N (1989) Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia. Lancet 1: 1334
Opalka B, Beer U, Niederle N, Wandl U, Kloke O, Schmidt CG (1989) Breakpoints outside the major bcr region (mbcr) do not define a clinically destinct group of CML patients. Proc Am Ass Cancer Res 30: 227
Opalka B, Wandl U, Kloke O, Beer U, Kirch HC, Niederle N (1989) Localization of the breakpoint in the mbcr does not correlate with the clinical course in CML patients undergoing interferon therapy. Blood 74: 367a
Ozer H, Mick R, Testa J, Arthur D, Cooper R, Pettenati M, Rao K, Peterson BA, Schiffer C, Bloomfield CD for CALGB (1989) Subcutaneous a-interferon produces clinical and cytogenetic remission in untreated chronic phase Philadelphia chromosome positive chronic myelogenous leukemia. Mol Biother 1 ( Suppl ): Abstr. 76
Parmeggiani L, Ferrant A, Rodhain J, Michaux JL, Sokal G (1987) Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 39: 228–232
Przepiorka D (1988) Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis. Cancer Genet Cytogenet 36: 117–122
Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU (1986) In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha- interferon: Correlation with receptor binding and induction of 2,5-oligoadenylate synthetase. Cancer Res 46: 4848–4852
Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.) 243: 290–293
Russo D, Fanin R, Zuffa E, Gallizia C, Michieli MG, Damiani D, Testoni N, Pecile V, Visani G, Colombini R, Tosi P, Baccarani M, Tura S (1989) Treatment of Ph + chronic myeloid leukemia by gamma interferon. Blut 59: 15–20
Sandberg A (1980) Chromosomes and causation of human cancer and leukemia XL. The Ph’ and other translocations in CML. Cancer 46: 2221–2226
Seewann HL, Gastl G, Lang A, Abbrederis K, Thaler J, Flener R, Huber CH (1988) Interferon-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 56: 161–163
Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Gutterman J, Yoffe G, Blick M (1988) Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 72: 485–490
Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (Lond.) 315: 550–554
Silver RT, Gale RP (1986) Chronic myeloid leukemia. Amer J Med 80: 1137–1147
Silver RT (1988) Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 2: 403
Stam K, Heisterkamp N, Grosveld G, De Klein A, Verma RS, Coleman M, Dosik H, Groffen J (1985) Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 313: 1429–1433
Talpaz M, McCredie KB, Mavligit GM, Gutterman JU (1983) Leukocyte interferon- induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–692
Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069
Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280–1288
Talpaz M, Kurzrock R, Kantarjian H, Keating M, Evans L, Saks S, Gutterman J (1988) Therapy of Philadelphia positive chronic myelogenous leukemia with recombinant alpha A interferon and recombinant gamma interferon. Blood 72: 229a
Talpaz M, Kurzrock R, Kantarjian H, O’Brien S, Gutterman JU (1989) Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 86: 554–558
Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163
Tichelli A, Gratwohl A, Berger C, Lori A, Würsch A, Dieterle A, Thomssen C, Nissen C, Holdener E, Speck B (1989) Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a. Blut 58: 15–19
Toretsky JA, Shahidi NT, Finlay JL (1986) Effects of recombinant human interferon gamma on hematopoietic progenitor cell growth. Exp Hematol 14: 182–186
Velu T, Delwiche F, Gangji D, Monsieur R, Flament J, Stryckmans P, Wybran J, Bellens R (1985) Therapeutic effect of human recombinant interferon-alpha-2c in essential thrombocythaemia. Oncology 42 (Suppl. 1): 10–14
Visani G, Russo D, Damiani D, Rizzi S, Motta MR, Lemoli RM, Poluzzi C, Fanin R, Zuffa E, Tosi P, Baccarani M, Tura S. (1988) Sensitivity of Ph 1 + CFU-GM to human recombinant interferon a and y in combination. Blut 57: 41–44
Wandl UB, Kloke O, Opalka B, Niederle N (1988) Suppressive effect of interferon alpha-2b on hematopoietic progenitor cells in patients with chronic myelogenous leukemia. In: Huhn D, Hellriegel KP, Niederle N (eds) Chronic Myelocytic Leukemia and Interferon. Pathophysiological, Clinical and Therapeutical Aspects. Springer, Berlin - Heidelberg - New York - London - Paris - Tokyo:84–90
Wickramasinghe SN, Peart S, Gill DS (1987) Alpha-interferon in primary idiopathic myelofibrosis. Lancet 2: 1524–1525
Williams CKO, Svet-Moldavskaya I, Vilcek J, Ohnuma T, Holland JF (1981) Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 38: 356–360
Wussow P von, Hartmann F, Freund M, Poliwoda H, Deicher H (1988) Leucocyte- derived interferon-alpha in patients with antibodies to recombinant IFN-a2b. Lancet 1: 882–883
Yoffe G, Blick M, Kantarjian H, Spitzer G, Gutterman J, Talpaz M (1987) Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 69: 961–963
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Niederle, N. (1990). Zur Behandlung myeloproliferativer Syndrome mit Interferonen. In: Niederle, N., von Wussow, P. (eds) Interferone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93383-7_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-93383-7_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-93384-4
Online ISBN: 978-3-642-93383-7
eBook Packages: Springer Book Archive